Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have completed participation in 1 of the core studies in adult rheumatoid arthritis.~Exclusion Criteria:~* Treatment with any investigational agent since the last administration of study drug in the core studies.~* Treatment with iv gamma globulin, plasmapheresis, or prosorba column since the last administration of study drug in the core studies.~* Treatment with an anti-TNF or anti-IL1 agent, a T-cell co-stimulation modulator, or any biologic since the last administration of study drug in the core studies.~* Immunization with a live/attenuated vaccine since the last administration of study drug in the core studies.~* Previous treatment with any cell-depleting therapies, including investigational agents.~* Parenteral, intramuscular, or intra-articular corticosteroids within 6 weeks prior to baseline in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).